Western Europe

NMSIC cut its commitment to Fund V due to the outperformance of investments in prior TDR funds, showing that even top managers are facing cutbacks.

The funds, secondaries and co-investment unit of the $1.4trn asset manager wants to see evidence of private equity professionals going into companies to 'do the work', managing partner Nitin Gupta tells PEI.

Inflationary pressure has been driven by different factors relative to previous iterations of rate hikes, Edwin Conway, global head of BlackRock Alternative Investors tells PEI.

Swedish insurer Skandia Asset Management doesn't just go with the flow. Its head of private equity and infrastructure, Daniel Winther, discusses his bearish outlook on of continuation funds, sponsors listing and ESG targets.

KKR’s co-heads of Europe, Philipp Freise and Mattia Caprioli, discuss investing during wartime, and doubling down on their partnership playbook for Europe.

Dedicated life sciences firms with strong AUM growth have been prime targets for larger GPs recently – here's a list of firms ranked by capital raised.

The $46bn medical research endowment wants to be aligned with GPs who roll over and compound their exposure to assets rather than those who sell down, Robert Coke, head of buyout and residential property, tells PEI.

'Partnering with a team that is deeply versed in the science like Sofinnova is critical to meaningfully scale and accelerate our investment activity,' said Apollo's Neil Mehta.

The fundraising platform plans to launch a European Long-Term Investment Fund alongside an as-yet-undetermined partner as early as Q4 2022, Moonfare founder Steffen Pauls tells PEI.

Fund XI is understood to be already more than 29% larger than its 2020-vintage predecessor, which raised €6.1bn against a €5bn target.